ReviewPharmaceutics2026
Applications of Pharmacometrics in Antibody-Drug Conjugate Development.
Review in Pharmaceutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Antibody-drug conjugates (ADCs), which integrate a cytotoxic drug known as the payload into a tumor-targeting monoclonal antibody via a linker, have emerged as promising candidates for cancer therapy and are a new avenue for targeted cancer therapy. The pharmacokinetic (PK) profiles of ADCs are distinctive due to their unique distribution, catabolism, and elimination. Their deconjugation in circulation and variations in the drug-to-antibody ratio increase the complexity of their PK profiles. Pharmacometric models depicting the PK properties and exposure-response (E-R) relationships of ADCs are important for optimizing dosing regimens and supporting decisions during ADC development. This review considers the PK profiles of ADCs, physiologically based PK models, semi-mechanistic and mechanistic PK models, population PK models, and E-R analyses for dose optimization. The prospects and challenges for ADCs, especially the urgent need for advanced analytical technology and modeling approaches, are also outlined.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.